A subanalysis of the Fracture Prevention Trial (388), which included 736 postmenopausal women with osteoporosis, creatinine concentrations ≤2.0 mg/dL, and normal serum PTH and calcium levels, found that a median 19-month course of teriparatide treatment (both at a dose of 20 mcg/day and 40 mcg/day) mediated statistically significant increases in lumbar spine and femoral neck BMD and significantly raised P1NP serum concentrations across renal function (eGFR from 30 to ≥80 mL/min/1.73 m2). This evidence concerns the gene PTH and osteoporosis.